Search filters

List of works by Antonio M Risitano

'Stealth' corporate innovation: an emerging threat for therapeutic drug development

scientific article published on 01 November 2019

Acute immune toxicity during anti-thymocyte globulin: That's CARPA!

scientific article

Advances in understanding the pathogenesis of acquired aplastic anaemia

scientific article published on 05 July 2018

Allogeneic stem cell transplantation for acquired pure red cell aplasia

scientific article published on 09 September 2019

Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.

scientific article published on 19 December 2017

Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development

scientific article published on 01 November 2019

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

scientific article published in June 2010

Eltrombopag for post-transplant cytopenias due to poor graft function

scientific article published on 24 January 2019

Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes

scientific article published on January 2007

Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SA

scientific article published on 28 April 2020

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party

scientific article published on 16 December 2019

IMPACT OF T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR IDIOPATHIC APLASTIC ANEMIA: A STUDY ON BEHALF OF THE EUROPEAN BLOOD AND MARROW TRANSPLANT (EBMT) SAA WORKING PARTY

scientific article published on 25 November 2018

Immune insights into AA.

scientific article published in May 2017

Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group

scientific article published on 08 April 2020

Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita

scientific article published on 09 July 2018

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

scientific article published on 24 May 2020

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

scientific article published on 13 September 2013

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia

scientific article published on 15 November 2013

Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Wor

scientific article published on 28 July 2015

T-PLL: harmonizing criteria for research

scientific article published on 01 October 2019

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

scientific article published on 14 September 2017

Toward complement inhibition 2.0: Next generation anti-complement agents for paroxysmal nocturnal hemoglobinuria

scientific article published on 4 January 2018

Transplant results in adults with Fanconi anaemia

scientific article published on 2 November 2017

Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes.

scientific article published on 9 May 2009